

IFW

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 00-078-D)


In the Application of:)	
)	
Luiz Belardinelli et al.)	
)	Art Unit: 1645
Serial No.: 10/614,702)	
)	
Confirmation No. 7957)	Examiner: Not Assigned
)	
Filed: July 3, 2003)	
)	
Title: Method of Identifying Partial Agonists)	
Of the A _{2A} Receptor)	

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


TRANSMITTAL LETTER

In regard to the above identified application:

1. We are transmitting herewith the attached:
 - a. Information Disclosure Statement
 - b. Form PTO 1449
 - c. Postcard
2. With respect to additional fees:
 - a. No fee is required.
3. Please charge any additional fees or credit overpayment to Deposit Account No. 13-2490. A duplicate copy of this sheet is enclosed.
4. CERTIFICATE OF MAILING UNDER 37 CFR § 1.8: The undersigned hereby certifies that this Transmittal Letter and the paper, as described in paragraph 1 hereinabove, are being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 5th day of August, 2004.

By: 
A Blair Hughes
Reg. No. 32,901

McDonnell Boehnen Hulbert & Berghoff LLP
300 S. Wacker Dr.
Chicago, Illinois 60606
312/913-0001



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 00-078-D)

PATENT

In the Application of:)	
)	
Luiz Belardinelli et al.)	
)	Art Unit: 1645
Serial No.: 10/614,702)	
)	
Confirmation No. 7957)	Examiner: Not Assigned
)	
Filed: July 3, 2003)	
)	
Title: Method of Identifying Partial Agonists)	
Of the A _{2A} Receptor)	

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. Section 1.97 - 1.99, the Applicant wishes to make the following references of record in the above-identified application. This Information Disclosure Statement is in compliance with the continuing duty of candor as set forth in 37 C.F.R. Section 1.56. Pursuant to 37 C.F.R. §1.98(d), copies of references numbered 1-8 are not provided herewith, since they were previously provided in the parent case, U.S. Patent Application Serial No. 09/792,617, filed on July 3, 2003. These references are also listed on the enclosed PTO Form 1449.

In the judgment of the undersigned, portions of the listed references may be material to the Examiner's consideration of the presently pending claims. This statement is not a representation that the listed references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. Section 102 or Section 103.

Applicants do not believe any fee is due with this submission. If this belief be in error and the Patent Office determines that the fee prescribed in the relevant portion of 37 C.F.R. Section 1.97 is applicable, the undersigned attorney by his signature hereby authorizes any such fee to be debited from Deposit Account 13-2490.

U. S. PATENTS

1. Vernani, U.S. Patent No. 6,026,317, issued February 15, 2000.

FOREIGN PATENT DOCUMENTS

2. PCT Patent No. WO 00/78778, published December 28, 2000
3. PCT Patent No. WO 00/78779, published December 28, 2000
4. EP Patent No. EP 0 354 638, published February 14, 1990.


OTHER DOCUMENTS

5. Glover, et al. "Characterization of a New, Highly Selective Adenosine A2A Receptor Vagionist with Potential Use in Pharmacologic Stress Perfusion Imaging", *Circulation*, vol. 110, p. 1-311 (1999)
6. Iskandrian, A, "Adenosine Myocardial Perfusion Imaging", *The Journal of Nuclear Medicine*", vol. 35, pp. 734-736 (1994).
7. Gao, et al., "Novel Short-Acting A2A Adenosine Receptor Agonists for Coronary Vasodilation: Inverse Relationship between Affinity and Duration of Action of A2A Agonists", *Journal of Pharmacology and Experimental Therapeutics*, vol. 298, pp. 209-218 (2001).
8. Xu, Jiang, et al., "Coronary vasodilation by a short acting, low affinity A2A adenosine receptor agonist in anesthetize closed chest dogs: a second generation of coronary artery pharmacologic stressor", *Circulation*, vol. 102, no. 18 p. II 810 (2000)

Respectfully submitted,
McDonnell Boehnen Hulbert & Berghoff LLP

Date: August 5, 2004

By:


A. Blair Hughes
Reg. No. 32,901

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.


00-078-D

Serial No.

10/614,702

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)



Applicant:

Luiz Belardinelli, et al.

Filing Date:

July 3, 2003

Group:

1645

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	6,026,317	2/15/00	Verani			

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Subclass	Translation	
					Yes	No
WO 00/78778	12/28/00	PCT				
WO 00/78779	12/28/00	PCT				
EP 0 354 638	2/14/90	EP				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

	Glover, et al. "Characterization of a New, Highly Selective Adenosine A2A Receptor Vagionist with Potential Use in Pharmacologic Stress Perfusion Imaging", <i>Circulation</i> , vol. 110, p. 1-311 (1999)
	Iskandrian, A, "Adenosine Myocardial Perfusion Imaging", <i>The Journal of Nuclear Medicine</i> , vol. 35, pp. 734-736 (1994).
	Gao, et al., "Novel Short-Acting A2A Adenosine Receptor Agonists for Coronary Vasodilation: Inverse Relationship between Affinity and Duration of Action of A2A Agonists", <i>Journal of Pharmacology and Experimental Therapeutics</i> , vol. 298, pp. 209-218 (2001).
	Xu, Jiang, et al., "Coronary vasodilation by a short acting, low affinity A2A adenosine receptor agonist in anesthetize closed chest dogs: a second generation of coronary artery pharmacologic stressor", <i>Circulation</i> , vol. 102, no. 18 p. II 810 (2000)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.